×
About 7,999 results

ALLMedicine™ Advanced Prostate Cancer Center

Research & Reviews  3,507 results

Patient-reported outcomes following neoadjuvant endocrine therapy, external beam radiat...
https://doi.org/10.1002/cam4.3895
Cancer Medicine; Yokomizo A, Koga H et. al.

May 1st, 2021 - We evaluated patient-reported outcomes (PRO) during neoadjuvant androgen deprivation therapy (ADT) plus external beam radiation therapy (EBRT) followed by either adjuvant continuous ADT (CADT) or intermittent ADT (IADT) for patients with locally a...

Impact of therapy on cancer metabolism in high-risk localized prostate cancer treated w...
https://doi.org/10.1002/pros.24134
The Prostate; Qu F, Gu Y et. al.

Apr 27th, 2021 - The application of neoadjuvant docetaxel and androgen deprivation therapy before radical prostatectomy has been clinically recognized as beneficial for the overall and progression-free survival of patients with advanced prostate cancer. However, t...

Lu177-PSMA therapy for men with advanced prostate cancer: 18 months survival analysis i...
https://doi.org/10.1111/1754-9485.13182
Journal of Medical Imaging and Radiation Oncology; Tatkovic A, McBean R et. al.

Apr 23rd, 2021 - Radioligand therapies, or 'theranostics', have an emerging role in patients with metastatic castration-resistant prostate cancer (mCRPC). Lutetium-177 (Lu), targeting prostate-specific membrane antigen (PSMA), has demonstrated promising outcomes i...

Exploratory assessment of pineal gland volume, composition, and urinary 6-sulfatoxymela...
https://doi.org/10.1002/pros.24130
The Prostate; Bazzi LA, Sigurdardottir LG et. al.

Apr 16th, 2021 - Melatonin levels are partially driven by the parenchyma volume of the pineal gland. Low urinary levels of 6-sulfatoxymelatonin have been associated with increased risk of advanced prostate cancer, but the relationship between pineal gland volume a...

Prednisone reduction for metastatic castration-resistant prostate cancer with recurrent...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8052077
Medicine Zhu X, Shi Z et. al.

Apr 13th, 2021 - Prednisone (10 mg/d) is often used in combination with docetaxel or abiraterone in the treatment of advanced prostate cancer. LATITUDE studies have confirmed that the combination of abiraterone and prednisone (5 mg/d) can be used for the treatment...

see more →

Guidelines  21 results

ASTRO Editorial: The AUA-ASTRO-SUO Advanced Prostate Cancer Guidelines: A Continued but...
https://doi.org/10.1016/j.prro.2020.10.002
Practical Radiation Oncology; Zietman AL,

Dec 14th, 2020 - ASTRO Editorial: The AUA-ASTRO-SUO Advanced Prostate Cancer Guidelines: A Continued but Changing Role for the Radiation Oncologist.|2020|Zietman AL, ,|

Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART II.
https://doi.org/10.1097/JU.0000000000001376
The Journal of Urology; Lowrance WT, Breau RH et. al.

Sep 22nd, 2020 - The summary presented herein represents Part II of the two-part series dedicated to Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline discussing prognostic and treatment recommendations for patients with castration-resistant disease. Please refer ...

Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART I.
https://doi.org/10.1097/JU.0000000000001375
The Journal of Urology; Lowrance WT, Breau RH et. al.

Sep 22nd, 2020 - The summary presented herein represents Part I of the two-part series dedicated to Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline discussing prognostic and treatment recommendations for patients with biochemical recurrence without metastatic di...

American Society for Radiation Oncology Editorial: Rapidly Evolving Technologies Relate...
https://doi.org/10.1016/j.prro.2020.06.009
Practical Radiation Oncology; Bauman GS, Jani AB

Sep 6th, 2020 - American Society for Radiation Oncology Editorial: Rapidly Evolving Technologies Related to Imaging Strategies for Advanced Prostate Cancer.|2020|Bauman GS,Jani AB,|

Optimizing the management of castration-resistant prostate cancer patients: A practical...
https://doi.org/10.1002/pros.24053
The Prostate REFERENCES; Shore ND, Drake CG et. al.

Aug 11th, 2020 - Advanced prostate cancer (PC) patients, especially those with metastatic prostate cancer (mPC), often require complex management pathways. Despite the publication of clinical practice guidelines by leading urological and oncological organizations ...

see more →

Drugs  15 results see all →

Clinicaltrials.gov  4,017 results

Patient-reported outcomes following neoadjuvant endocrine therapy, external beam radiat...
https://doi.org/10.1002/cam4.3895
Cancer Medicine; Yokomizo A, Koga H et. al.

May 1st, 2021 - We evaluated patient-reported outcomes (PRO) during neoadjuvant androgen deprivation therapy (ADT) plus external beam radiation therapy (EBRT) followed by either adjuvant continuous ADT (CADT) or intermittent ADT (IADT) for patients with locally a...

Impact of therapy on cancer metabolism in high-risk localized prostate cancer treated w...
https://doi.org/10.1002/pros.24134
The Prostate; Qu F, Gu Y et. al.

Apr 27th, 2021 - The application of neoadjuvant docetaxel and androgen deprivation therapy before radical prostatectomy has been clinically recognized as beneficial for the overall and progression-free survival of patients with advanced prostate cancer. However, t...

Cardiovascular Events With Transdermal Estradiol vs LHRH Agonists for Androgen Suppression in Advanced Prostate Cancer
https://ascopost.com/issues/april-25-2021/cardiovascular-events-with-transdermal-estradiol-vs-lhrh-agonists-for-androgen-suppression-in-advanced-prostate-cancer/

Apr 24th, 2021 - In an analysis from the UK phase II/III PATCH trial reported in The Lancet, Langley et al found no differences in cardiovascular event rates over long-term follow-up with the use of a transdermal estradiol patch vs luteinizing hormone-releasing ho...

Lu177-PSMA therapy for men with advanced prostate cancer: 18 months survival analysis i...
https://doi.org/10.1111/1754-9485.13182
Journal of Medical Imaging and Radiation Oncology; Tatkovic A, McBean R et. al.

Apr 23rd, 2021 - Radioligand therapies, or 'theranostics', have an emerging role in patients with metastatic castration-resistant prostate cancer (mCRPC). Lutetium-177 (Lu), targeting prostate-specific membrane antigen (PSMA), has demonstrated promising outcomes i...

Exploratory assessment of pineal gland volume, composition, and urinary 6-sulfatoxymela...
https://doi.org/10.1002/pros.24130
The Prostate; Bazzi LA, Sigurdardottir LG et. al.

Apr 16th, 2021 - Melatonin levels are partially driven by the parenchyma volume of the pineal gland. Low urinary levels of 6-sulfatoxymelatonin have been associated with increased risk of advanced prostate cancer, but the relationship between pineal gland volume a...

see more →

News  437 results

Study Shows UK Sniffer Dogs Have a Nose for Prostate Cancer
https://www.medscape.com/viewarticle/946111

Feb 18th, 2021 - The results of a trial led by Medical Detection Dogs in Milton Keynes suggest that trained dogs can detect advanced prostate cancer in urine samples with high specificity and sensitivity. The study, published in  PLoS One,  tested the clinical fea...

Relugolix Confirmed to Cut Menstrual Bleed by Half in Most Women With Fibroids
https://www.medscape.com/viewarticle/945995

Feb 17th, 2021 - (Reuters Health) - Daily relugolix therapy cuts menstrual bleeding by at least half without affecting bone density in 71% of women with uterine fibroids, according to results from the LIBERTY 2 trial, published by The New England Journal of Medici...

Whole-Pelvis Radiotherapy for High-Risk Prostate Cancer
https://www.medscape.com/viewarticle/943903

Jan 10th, 2021 - Irradiating the whole pelvis rather than just the prostate reduces the likelihood of recurrence in men with high-risk locally advanced prostate cancer, according to a randomized controlled trial. Results from the trial, called POP-RT, were reporte...

FDA OKs First Oral Hormone Tx for Advanced Prostate Cancer
https://www.medscape.com/viewarticle/942933

Dec 17th, 2020 - The US Food and Drug Administration (FDA) today approved an oral form of androgen deprivation therapy (ADT) known as relugolix (Orgovyx) for the treatment of adult patients with advanced prostate cancer. Relugolix is an oral gonadotropin-releasing...

Longer Survival With Sipuleucel-T in Advanced Prostate Cancer
https://www.staging.medscape.com/viewarticle/940590

Nov 8th, 2020 - The first and only immunotherapy product for advanced cancer, sipuleucel-T (Provenge), has not been widely used clinically since its launch 10 years ago, and has been largely eclipsed by two drugs launched since then — the androgen-receptor signal...

see more →

Patient Education  2 results see all →